Laxminarayan Bhat

This inventor holds 39 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 5 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Reviva Pharmaceuticals, Inc., Xenoport, Inc., Revivia Pharmaceuticals, Inc.. Active years: 2005-2024.

USPTO Granted Patents = 39 (Patent Applications = 6)

% Patents Active = 69.2

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 2.5

ph-index = 6

Forward Citations = 203(Granted Patents)

Location History:

San Jose, CA (US) (2012 - 2013)
Santa Clara, CA (US) (2005 - 2019)
Cupertino, CA (US) (2011 - 2024)

Company Filing History:

27 out of 27

Reviva Pharmaceuticals, Inc.

Revivia Pharmaceuticals, Inc.

Years Active: 2005-2024

Loading Chart...

Areas of Expertise:

Pulmonary Fibrosis

Pulmonary Hypertension

ADHD Treatment

Cycloalkylmethylamines

Arylpiperazine Derivatives

Prodrugs

Cholinesterase Inhibitors

Bioavailability Enhancement

Phenylcycloalkylmethylamine

Quinazolinedione Derivatives

Indanone Based Compounds

Acyloxyalkyl Compounds

39 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12053477 - Methods for treating pulmonary fibrosis (2024-08-06),

2. 10441590 - Methods for treating pulmonary hypertension (2019-10-15),

3. 10035761 - Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives (2018-07-31),

4. 9975862 - Arylpiperazine derivatives and methods of utilizing same (2018-05-22),

5. 9907803 - Methods for treating attention deficit hyperactivity disorder (2018-03-06),

6. 9695116 - Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives (2017-07-04),

7. 9604944 - Arylpiperazine derivatives and methods of utilizing same (2017-03-28),

8. 9302981 - Synthesis, methods of using, and compositions of cycloalkylmethylamines (2016-04-05),

9. 9296681 - Cycloalkylmethylamines (2016-03-29),

10. 9255076 - Arylpiperazine derivatives and methods of utilizing same (2016-02-09),

11. 9238625 - Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives (2016-01-19),

12. 9096515 - Methods of using cycloalkylmethylamine derivatives (2015-08-04),

13. 8980883 - Arylpiperazine derivatives and methods of utilizing same (2015-03-17),

14. 8859552 - Methods of utilizing arylpiperazine derivatives (2014-10-14),

15. 8669285 - Synthesis, methods of using, and compositions of cycloalkylmethylamines (2014-03-11),

Title: Laxminarayan Bhat: An Innovator in Pulmonary Treatments

Introduction

Laxminarayan Bhat is a distinguished inventor based in Cupertino, California, known for his significant contributions in the field of pharmaceuticals. With an impressive portfolio of 39 patents, he has emerged as a prominent figure in the development of innovative treatments for pulmonary diseases.

Latest Patents

Among his latest inventions, Bhat has patented methods for treating pulmonary fibrosis and pulmonary hypertension. The method for treating pulmonary fibrosis involves the use of arylpiperazine derivatives, specifically through the administration of a compound of Formula 1 to patients in need. Similarly, his method for treating pulmonary hypertension also utilizes arylpiperazine derivatives, providing essential therapeutic options for patients suffering from these challenging conditions.

Career Highlights

Laxminarayan Bhat has built a remarkable career, contributing his expertise to notable companies such as Reviva Pharmaceuticals and Xenoport. His work in these organizations has been instrumental in advancing the development of pharmaceutical innovations, particularly in addressing complex health issues related to pulmonary diseases.

Collaborations

Throughout his career, Bhat has collaborated with talented professionals like Kouacou Adiey and Prabhu Prasad Mohapatra. These partnerships have fostered a dynamic and innovative environment, leading to significant advancements in the pharmaceutical field.

Conclusion

Laxminarayan Bhat's contributions to medical science through his patents and collaborations exemplify the spirit of innovation. His work not only highlights the potential of arylpiperazine derivatives in treating serious lung conditions but also showcases the importance of collaboration in driving meaningful advancements in healthcare.